Violeta Serra

17.3k citations
86 papers · 7.2k · 6 hit papers · h-index 34

Impact in

  • Aging top 1%
  • Oncology top 0.5%
    • PARP inhibition in cancer therapy
    • HER2/EGFR in Cancer Research
    • Cancer-related Molecular Pathways

Papers in

    • PARP inhibition in cancer therapy 20
    • HER2/EGFR in Cancer Research 12
    • Cancer-related Molecular Pathways 10
    • DNA Repair Mechanisms 16
    • PI3K/AKT/mTOR signaling in cancer 12

Violeta Serra

76 papers receiving 7.0k citations

Violeta Serra's Hit Papers

A decade of clinical development of PARP inhibitors in perspective 2019 · 517 citations
5170+6+12Years since publication250500750

Peers

Violeta Serra
Comparison fields: 5 of 130
  • Aging 259
  • Oncology 2.9k
  • Genetics 628
  • Cancer Research 868
  • Molecular Biology 3.9k
Replace Eliot M. Rosen with:
Eliot M. Rosen United States
Rugang Zhang United States
F. Michael Yakes United States
Todd Waldman United States
Thomas Kuilman Netherlands
Peter Atadja United States
Christopher J. Bakkenist United States
Jordan S. Fridman United States
Naomi Goldfinger Israel
Vassiliki Karantza United States
Violeta Serra relative to Eliot M. Rosen United States Eliot M. Rosen's profile →
Citations per field
00.5×5.7×
Eliot M. Rosen · 1×
Citations per year

Countries citing papers authored by Violeta Serra

Since Specialization
Citations

This map shows the geographic impact of Violeta Serra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Violeta Serra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Violeta Serra more than expected).

Fields of papers citing papers by Violeta Serra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Violeta Serra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Violeta Serra. The network helps show where Violeta Serra may publish in the future.

Co-authors

The 25 scholars most cited alongside Violeta Serra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Violeta Serra Line = papers co-authored together Violeta Serra links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 86 papers — load more, or switch the sort, to bring in the rest.

#Work
1
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Hit paper breakdown →
2011773
2
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Hit paper breakdown →
2008653
3
Development of PI3K inhibitors: lessons learned from early clinical trials
Hit paper breakdown →
2013640
4
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
Hit paper breakdown →
2016534
5
A decade of clinical development of PARP inhibitors in perspective
Hit paper breakdown →
2019517
6 2011448
7 2008397
8
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Hit paper breakdown →
2014352
9 2020285
10 2011271
11 2000258
12 2003227
13 2019157
14 2012132
15 2013113
16 200597
17 200084
18 201877
19 202165
20 201760

About Violeta Serra

Violeta Serra is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Physiology, having authored 86 papers that have together received 7.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (20 papers), DNA Repair Mechanisms (16 papers), Advanced Breast Cancer Therapies (14 papers), HER2/EGFR in Cancer Research (12 papers), PI3K/AKT/mTOR signaling in cancer (12 papers), Cancer-related Molecular Pathways (10 papers), Cancer Genomics and Diagnostics (9 papers) and Telomeres, Telomerase, and Senescence (8 papers). The work is most often cited by research in Aging (259 citations), Oncology (2.9k citations), Genetics (628 citations), Cancer Research (868 citations) and Molecular Biology (3.9k citations). Violeta Serra has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Maurizio Scaltriti, Marta Guzmán, Pieter J.A. Eichhorn, Thomas von Zglinicki, José Baselga, José Baselga and Sarat Chandarlapaty. Their work appears in journals such as Cancer Research, Annals of Oncology, Molecular Cancer Therapeutics, European Journal of Cancer and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact